SFE Investment Counsel’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-44,000
| Closed | -$180K | – | 124 |
|
|
2022
Q1 | $180K | Hold |
44,000
| – | – | 0.05% | 122 |
|
|
2021
Q4 | $157K | Hold |
44,000
| – | – | 0.04% | 119 |
|
|
2021
Q3 | $160K | Sell |
44,000
-4,000
| -8% | -$16.2K | 0.04% | 118 |
|
|
2021
Q2 | $209K | Sell |
48,000
-10,000
| -17% | -$40.7K | 0.06% | 115 |
|
|
2021
Q1 | $238K | Sell |
58,000
-2,000
| -3% | -$8.67K | 0.07% | 112 |
|
|
2020
Q4 | $239K | Hold |
60,000
| – | – | 0.08% | 107 |
|
|
2020
Q3 | $162K | Hold |
60,000
| – | – | 0.06% | 108 |
|
|
2020
Q2 | $165K | Hold |
60,000
| – | – | 0.07% | 102 |
|
|
2020
Q1 | $142K | Hold |
60,000
| – | – | 0.08% | 101 |
|
|
2019
Q4 | $282K | Hold |
60,000
| – | – | 0.12% | 99 |
|
|
2019
Q3 | $201K | Hold |
60,000
| – | – | 0.09% | 115 |
|
|
2019
Q2 | $197K | Hold |
60,000
| – | – | 0.08% | 109 |
|
|
2019
Q1 | $182K | Hold |
60,000
| – | – | 0.08% | 112 |
|
|
2018
Q4 | $163K | Hold |
60,000
| – | – | 0.08% | 116 |
|
|
2018
Q3 | $202K | Hold |
60,000
| – | – | 0.08% | 125 |
|
|
2018
Q2 | $155K | Hold |
60,000
| – | – | 0.06% | 124 |
|
|
2018
Q1 | $132K | Hold |
60,000
| – | – | 0.07% | 105 |
|
|
2017
Q4 | $119K | Hold |
60,000
| – | – | 0.05% | 113 |
|
|
2017
Q3 | $194K | Hold |
60,000
| – | – | 0.08% | 113 |
|
|
2017
Q2 | $193K | Hold |
60,000
| – | – | 0.08% | 107 |
|
|
2017
Q1 | $170K | Hold |
60,000
| – | – | 0.06% | 109 |
|
|
2016
Q4 | $123K | Hold |
60,000
| – | – | 0.05% | 103 |
|
|
2016
Q3 | $63K | Hold |
60,000
| – | – | 0.03% | 91 |
|
|
2016
Q2 | $63K | Hold |
60,000
| – | – | 0.03% | 92 |
|
|
2016
Q1 | $52K | Hold |
60,000
| – | – | 0.02% | 95 |
|
|
2015
Q4 | $73K | Hold |
60,000
| – | – | 0.03% | 92 |
|
|
2015
Q3 | $102K | Hold |
60,000
| – | – | 0.05% | 92 |
|
|
2015
Q2 | $125K | Buy |
60,000
+35,000
| +140% | +$84.9K | 0.05% | 99 |
|
|
2015
Q1 | $68K | Hold |
25,000
| – | – | 0.03% | 90 |
|
|
2014
Q4 | $64K | Hold |
25,000
| – | – | 0.03% | 89 |
|
|
2014
Q3 | $46K | Hold |
25,000
| – | – | 0.02% | 87 |
|
|
2014
Q2 | $67K | Hold |
25,000
| – | – | 0.03% | 86 |
|
|
2014
Q1 | $87K | Hold |
25,000
| – | – | 0.04% | 85 |
|
|
2013
Q4 | $112K | Hold |
25,000
| – | – | 0.05% | 87 |
|
|
2013
Q3 | $101K | Sell |
25,000
-5,000
| -17% | -$21.8K | 0.05% | 81 |
|
|
2013
Q2 | $125K | Buy |
+30,000
| New | +$116K | 0.06% | 78 |
|
Other funds holding ATRS
SFE Investment Counsel's ATRS Position: Q2 2022 in Review
SFE Investment Counsel sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 44,000 shares — an estimated $180K sold.
SFE Investment Counsel first reported a position in ATRS in Q2 2013 and held it in 36 quarters. The position peaked at $282K in Q4 2019. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- SFE Investment Counsel reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- SFE Investment Counsel sold 44,000 Antares Pharma, Inc. shares in Q2 2022, an estimated $180K.
- SFE Investment Counsel first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 36 quarters.
- SFE Investment Counsel's Antares Pharma, Inc. position peaked at $282K in Q4 2019.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on SFE Investment Counsel's 13F filing for Q2 2022, filed 10 Aug 2022.